Drug intelligence / Profile preview

MRT-1 + MRT-2

Development stage: Preclinical
Lead developer: Oncodesign Precision Medicine
Modality: Small Molecules
Administration: Intravenous

Overview

MRT-1 + MRT-2 is a combination or pair of preclinical small molecule programs developed by Oncodesign Precision Medicine for the treatment of oncology. These assets are derived from Oncodesign's proprietary Nanocyclix platform, which focuses on the design of highly selective macrocyclic kinase inhibitors. While the specific biological targets for MRT-1 and MRT-2 remain undisclosed in public pipeline disclosures, they are part of the company's precision medicine portfolio aimed at addressing unmet needs in cancer therapy through targeted kinase modulation.

Other names: MRT 1 and 2MRT1 and 2MRT-1 and 2

Beyond the preview

Go deeper on MRT-1 + MRT-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRT-1 + MRT-2.

Explore the full profile